200–300 mcg — reported, not studied
200–300 mcg two or three times a day under the skin, which is not how any of it was studied. Every trial dose above went into a vein, in hospital, after bowel surgery.
| Water added | Concentration | Draw, low to high |
|---|---|---|
| 2 mL | 2.50 mg/mL | 8.0 to 12.0 units |
| 3 mL | 1.67 mg/mL | 12.0 to 18.0 units |
indirect evidenceDominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or safe · retrieved 2026-08-12
